4 Results
October 2022
Three-dose hepatitis B vaccine regimen protects people with HIV
October 20, 2022
A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsors the ongoing Phase 3 ACTG A5379 clinical study.
August 2022
NIH Updates Hepatitis B Strategic Research Plan
August 1, 2022
The National Institutes of Health has updated its Strategic Plan for NIH Research to Cure Hepatitis B, a roadmap for ending the hepatitis B epidemic, focused on developing a cure as well as improved strategies for vaccination, screening and follow-up care. The revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology.
September 2021
NIAID Scientists Find a Key to Hepatitis C Entry into Cells
September 21, 2021
Understanding Structure of HCV Proteins Could Aid in Vaccine Development
May 2019
Trial Evaluating Experimental Hepatitis C Vaccine Concludes
May 29, 2019
An experimental vaccine was not found to be effective at preventing chronic hepatitis C virus (HCV) infection in adults, NIAID-supported study reports.